solu-cortef stungulyfsstofn og leysir, lausn 250 mg
pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 250 mg
ziprasidon actavis hart hylki 20 mg
actavis group ptc ehf. - ziprasidonum hýdróklóríð - hart hylki - 20 mg
ziprasidon actavis hart hylki 40 mg
actavis group ptc ehf. - ziprasidonum hýdróklóríð - hart hylki - 40 mg
ziprasidon actavis hart hylki 60 mg
actavis group ptc ehf. - ziprasidonum hýdróklóríð - hart hylki - 60 mg
ziprasidon actavis hart hylki 80 mg
actavis group ptc ehf. - ziprasidonum hýdróklóríð - hart hylki - 80 mg
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - augnlækningar - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.